https://scholars.lib.ntu.edu.tw/handle/123456789/485687
標題: | Medulloblastoma in adults: Treatment outcome, relapse patterns, and prognostic factors | 作者: | SHIH-FAN LAI CHUN-WEI WANG YU-HSUAN CHEN KENG-HSUEH LAN CHIA-HSIEN CHENG ANN-LII CHENG SUNG-HSIN KUO |
公開日期: | 2012 | 卷: | 188 | 期: | 10 | 起(迄)頁: | 878-886 | 來源出版物: | Strahlentherapie und Onkologie | 摘要: | Background and purpose. In this study, the clinical outcome and prognostic factors of adult medulloblastoma patients receiving multimodal treatment were investigated.Patients and methods. The clinical manifestations, treatment variables, and outcome of adult patients with medulloblastoma at our institution between 1983 and 2009 were retrospectively reviewed.Results. A total of 20 adult patients were included (median age 22 years). Craniospinal irradiation (CSI) was given postoperatively. The craniospinal axis received a median of 30 Gy (range 23.4-39.6 Gy) in fractions of 1.6-2 Gy/day, and the tumor was boosted to a total median dose of 50 Gy (range 50-55.25 Gy). The 3-year disease-free survival (DFS) and overall survival (OS) rates for all patients were 45% and 50%, respectively. In univariate analysis, Karnofsky Performance Scale (KPS) >70, neurologic symptoms duration >30 days, lateral tumor location, standard risk patients, no hydrocephalus, radiotherapy (RT) treatment field (CSI+brain boost), and CSI dose ?30 Gy were associated with better DFS. Standard-risk patients, RT treatment field (CSI+brain boost), and CSI dose ?30 Gy were also significantly associated with better OS.Conclusion. The combined modality treatment results in a favorable outcome for adult medulloblastoma patients. Further investigation of the prognostic factors, radiation-related factors, and systemic chemotherapy is needed. ? Springer-Verlag 2012. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84866708023&doi=10.1007%2fs00066-012-0168-2&partnerID=40&md5=697c9f80bd652b5a4494ef24dd327928 https://scholars.lib.ntu.edu.tw/handle/123456789/485687 |
ISSN: | 0179-7158 | DOI: | 10.1007/s00066-012-0168-2 | SDG/關鍵字: | carmustine; cisplatin; cyclophosphamide; doxorubicin; etoposide; ifosfamide; methotrexate; vincristine; adjuvant therapy; adolescent; adult; adult disease; article; cancer adjuvant therapy; cancer combination chemotherapy; cancer patient; cancer prognosis; cancer radiotherapy; cancer relapse; cancer risk; cancer survival; clinical article; disease free survival; female; human; Karnofsky Performance Status; male; medulloblastoma; multimodality cancer therapy; neurosurgery; overall survival; partial body radiation; postoperative care; radiation dose fractionation; retrospective study; treatment outcome; Adult; Aged; Cerebellar Neoplasms; Female; Germany; Humans; Male; Medulloblastoma; Middle Aged; Neoplasm Recurrence, Local; Prevalence; Prognosis; Radiotherapy, Conformal; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。